June 2023 in “BMC Pharmacology and Toxicology” The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.
34 citations
,
August 2002 in “British Journal of Dermatology” ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.
1 citations
,
March 2023 in “Journal of the American College of Cardiology” 26 citations
,
June 2020 in “The Journal of Allergy and Clinical Immunology In Practice” A patient developed a severe skin reaction and died after taking hydroxychloroquine for COVID-19.
December 2025 in “Chemical Engineering Journal” 4 citations
,
March 2025 in “The Journal of Dermatology” Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.
January 2026 in “Clinics and Practice” Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.
9 citations
,
May 2019 in “Journal of dermatological treatment” Apremilast helps regrow hair in hard-to-treat alopecia areata.
September 2023 in “PubMed” Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
2 citations
,
October 2024 in “Phytochemistry Reviews” Abrus precatorius has medicinal benefits but can be toxic.
Eclipta alba can effectively kill worms like the drug Albendazole.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
December 2025 in “Pharmaceutics” Araliadiol may help reduce skin aging and inflammation without killing cells.
3 citations
,
November 2024 in “Clinical Research” Deuruxolitinib is FDA-approved for treating severe alopecia areata.
December 2025 in “International Journal of Innovative Technologies in Social Science” Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
42 citations
,
April 2021 in “Journal of clinical pharmacology” Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.
September 2024 in “Journal of the American Academy of Dermatology” AH-001 could be a safer and more effective treatment for hair loss.
36 citations
,
November 2020 in “Journal of The European Academy of Dermatology and Venereology” 5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
November 2015 in “Clin-Alert” Some medications and supplements can cause serious side effects, including hair loss, heart rhythm problems, liver injury, and other health issues.
September 2024 in “Drugs & Therapy Perspectives” Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
March 2026 in “Food Science & Nutrition” Arachis hypogaea L. root extract reduces prostate enlargement and inflammation in mice.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
February 2024 in “Archiv EuroMedica” Annurca apple extract may help with hair growth and prevent hair loss.
52 citations
,
May 2011 in “Journal of Neuroendocrinology” PEA boosts allopregnanolone production and reduces oxidative stress in brain cells.